The aim of this study was to identify gene expression profiles in peripheral blood mononuclear cells (PBMCs) from sporadic amyotrophic lateral sclerosis (sALS) patients to gain insights into the pathogenesis of ALS. We found that upregulation of LPS/TLR4-signaling associated genes was observed in the PMBCs from sALS patients after short-term cultivation, and that elevated levels of gene expression correlated with degree of peripheral blood monocyte activation and plasma LPS levels in sALS. Similar patterns of gene expression were reproduced in LPS stimulated PBMCs from healthy controls. These data suggest that chronic monocyte/macrophage activation may be through LPS/TLR4-signaling pathways in ALS.
Introduction
Amyotrophic lateral sclerosis (ALS) is a debilitating neurological disorder in which neurodegeneration occurs in concert with an ongoing inflammatory process (McGeer and McGeer, 2002) . ALS manifests as muscle weakness and paralysis with death ensuing for most patients within 5 years of symptom onset. Almost 90% of ALS patients are characterized as having sporadic ALS (sALS) with 10% having a familial form, a subset of whom have point mutations in their superoxide dismutase (SOD) gene. Evidence accumulating over the past decade has indicated that inflammation and immune activation may be commonly involved in the pathogenesis of ALS (Alexianu et al., 2001; Graves et al., 2004; Henkel et al., 2004; McGeer and McGeer, 2002; Simpson et al., 2004; Zhang et al., 2005) . Neuropathologically, ALS is characterized by motor neuron degeneration with ubiquinated inclusions in the spinal cord and motor cortex. The neuropathologic lesions are surrounded by activated microglia in both the familial and sporadic forms of ALS disease (Kawamata et al., 1992; McGeer and McGeer, 2002) , which may play an active role in ALS disease progression (Beers et al., 2006; Boillee et al., 2006) .
Along with activated resident microglia, large numbers of infiltrating macrophages are present in sALS spinal cord lesions. Abnormal secretion of macrophage activation products and proinflammatory cytokines, such as monocyte chemoattractant protein-1 (MCP-1) (Baron et al., 2005; Henkel et al., 2004; Simpson et al., 2004; Wilms et al., 2003; Zhang et al., 2006) , and interleukin-6 (IL-6) (Ono et al., 2001; Sekizawa et al., 1998) have been reported in cerebral spinal fluid (CSF) and sera in patients with ALS. Enhanced levels of tumor necrosis factor-α (TNF-α) have also been seen in the blood of ALS patients (Babu et al., 2008; Cereda et al., 2008; Poloni et al., 2000) . Patients with sALS exhibit elevated levels of CD16+ monocytes in peripheral blood (Zhang et al., 2005) . These CD16+ ALS associated monocytes are characterized by high expression of monocyte activation marker HLA-DR and low expression of the MCP-1 receptor, CCR2 (Zhang et al., 2006) . In addition, our more recent study found significantly increased levels of plasma endotoxin/lipopolysaccharide (LPS), a systemic macrophage activator, in sALS patients, and that increased LPS levels correlated with degree of abnormally activated monocyte/macrophages in the peripheral blood. Finally, chronic stimulation of innate immunity with LPS has been shown to accelerate the disease course in SOD1 transgenic mice (Nguyen et al., 2004) .
Endotoxin/lipopolysaccharide is a potent inflammatory stimulus and immunostimulatory product (Takeda et al., 2003) and induces its effects through stimulation of CD14-bearing inflammatory cells (Flo et al., 2000; Tobias et al., 1999) . LPS associated toxicity is mediated through systemic monocyte/macrophage and endothelial cell activation with release of inflammatory cytokines such as TNF-α and IL-6 (Beutler et al., 1985; Danner et al., 1991; Okusawa et al., 1988; Tracey et al., 1986) . The effects of LPS are mediated primarily through toll-like receptor 4 (TLR4). Journal of Neuroimmunology 230 (2011) 114-123 
